gallbladder pain semaglutide Ozempic and GLP-1 Drugs: Risk of Severe Side Effects GLP-1 Medications: What You Need

DeFeudis Professor of Biomedical Research University of Massachusetts Medical School Copyright 2015-2026 Linus Pauling Institute Figure Alternative Text Figure

The primary composite outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke

Heat Maps Regional and segment-level opportunity intensity

2022 Sep 1;20(1):272

Keep Accountability in Place A recent analysis presented at the 2025 American Diabetes Association conference found that patients who maintained monthly check-ins with their care team regained significantly less weight than those who stopped follow-up visits

Wegovy in patients with CVD who will be eligible under NICE plans NICE has recommended that patients with established cardiovascular disease who are also overweight should be offered semaglutide (Wegovy)